TY - JOUR
T1 - Metastatic and triple-negative breast cancer
T2 - challenges and treatment options
AU - Al-Mahmood, Sumayah
AU - Sapiezynski, Justin
AU - Garbuzenko, Olga B.
AU - Minko, Tamara
N1 - Publisher Copyright:
© 2018, The Author(s).
PY - 2018/10/1
Y1 - 2018/10/1
N2 - The major current conventional types of metastatic breast cancer (MBC) treatments include surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy. Introducing biological drugs, targeted treatment and gene therapy can potentially reduce the mortality and improve the quality of life in patients with MBC. However, combination of several types of treatment is usually recommended. Triple negative breast cancer (TNBC) accounts for 10–20% of all cases of breast carcinoma and is characterized by the low expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). Consequently, convenient treatments used for MBC that target these receptors are not effective for TNBC which therefore requires special treatment approaches. This review discusses the occurrence of MBC, the prognosis and predictive biomarkers of MBC, and focuses on the novel advanced tactics for treatment of MBC and TNBC. Nanotechnology-based combinatorial approach for the suppression of EGFR by siRNA and gifitinib is described.
AB - The major current conventional types of metastatic breast cancer (MBC) treatments include surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy. Introducing biological drugs, targeted treatment and gene therapy can potentially reduce the mortality and improve the quality of life in patients with MBC. However, combination of several types of treatment is usually recommended. Triple negative breast cancer (TNBC) accounts for 10–20% of all cases of breast carcinoma and is characterized by the low expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). Consequently, convenient treatments used for MBC that target these receptors are not effective for TNBC which therefore requires special treatment approaches. This review discusses the occurrence of MBC, the prognosis and predictive biomarkers of MBC, and focuses on the novel advanced tactics for treatment of MBC and TNBC. Nanotechnology-based combinatorial approach for the suppression of EGFR by siRNA and gifitinib is described.
KW - Combinatorial treatment of breast cancer
KW - EGFR
KW - Gefitinib
KW - Liposomes
KW - siRNA
UR - http://www.scopus.com/inward/record.url?scp=85052386409&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052386409&partnerID=8YFLogxK
U2 - 10.1007/s13346-018-0551-3
DO - 10.1007/s13346-018-0551-3
M3 - Review article
C2 - 29978332
AN - SCOPUS:85052386409
SN - 2190-393X
VL - 8
SP - 1483
EP - 1507
JO - Drug Delivery and Translational Research
JF - Drug Delivery and Translational Research
IS - 5
ER -